The North America Sexually Transmitted Diseases (STD) Testing Market would witness market growth of 4.3% CAGR during the forecast period (2021-2027).
The prevalence of sexually transmitted diseases has increased as a result of a surge in unprotected intercourse, which would fuel the need for sexually transmitted disease testing globally. Even if a person has no symptoms but has had unprotected sex, doctors will usually recommend STD testing. Viral load monitoring, genotyping, immunoassays, and molecular diagnostics are some of the STD diagnostics available in the market.
Simultaneous testing for many targets is one way to improve testing reliability. Compensating for genotype changes, mutations, and mismatches have boosted the probability of detection for infections such as HIV, syphilis, hepatitis C virus (HCV), and chlamydia, and can help to detect cases of co-infection in advance.
According to CDC, in 2019, 2.5 million cases of gonorrhoea, chlamydia, and syphilis, which are the three most common STDs, were reported in the US. Between 2015 and 2019, there was an almost 30% increase in these reportable STDs. Owing to this rising prevalence of STDs in the US and other developed nations and the growing initiatives to aware people regarding STDs, the demand for STD testing would increase in the coming years. For instance, programs initiated by CDC stated that innovative STD testing procedures are crucial for STD prevention. STD care is growing beyond the clinic environment, with new options for phone, video, and online health care appointments. Expanding these measures can assist authorities in reducing STDs and addressing previously unresolved health-care access issues.
The US market dominated the North America Sexually Transmitted Diseases (STD) Testing Market by Country 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $25.63 billion by 2027. The Canada market is poised to grow at a CAGR of 6.6% during (2021 - 2027). Additionally, The Mexico market would display a CAGR of 5.7% during (2021 - 2027).
Based on Disease Type, the market is segmented into Chlamydia, Herpes simplex, Gonorrhea, Syphilis, Human papillomavirus (HPV), and Other Disease. Based on the Location of Testing, the market is segmented into Laboratory Testing and Point of care (POC) Testing. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Sexually Transmitted Diseases (STD) Testing Market is Estimated to reach $120 Billion by 2027, at a CAGR of 4.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include BioMérieux S.A., Abbott Laboratories, Becton, Dickinson and Company, Hologic, Inc., Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., DiaSorin Molecular LLC, Danaher Corporation, Bio-Rad Laboratories, Inc., and OraSure Technologies, Inc.
By Disease Type
By Location of Testing
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
